With more than 20 years of experience in creating dynamic biotech and pharmaceutical companies, Jeff Aronin is a true pioneer in healthcare, and in helping patients prevail over serious illnesses.
Jeff Aronin has served in a number of senior leadership positions and has founded other companies. He was CEO of Ovation Pharmaceuticals, Inc., Lundbeck, Inc., in addition to his current role as chairman and CEO of Paragon Biosciences, a leading incubator of and investor in innovative biotech companies (Linkedin).
Aronin’s companies have a well-earned track record of success in getting new medicines approved for people who have rare or neglected illnesses. The team at Paragon Biosciences has had 13 new medicines approved by Food and Drug Administration, a success rate on par with or better than many large biotech and pharma companies.
Paragon Biosciences is focused on enhancing the lives of patients with unmet medical needs. Paragon’s team deeply studies patient needs, to truly understand the underlying cause of illness, and then focuses on securing breakthrough science and strategically building focused companies to bring important medicines to market.
Paragon’s uses its entrepreneurial skills to help incubate promising biotech startups to help further improve the efficiency of the work needed to get medicines approved.